Phase II randomized trial of gallium nitrate plus fluorouracil versus methotrexate, vinblastine, doxorubicin, and cisplatin in patients with advanced transitional-cell carcinoma

Journal of Clinical Oncology

Volumn 15, Issue 6, 1997, Pages 2449-2455

  McCaffrey, John A ^a   Hilton, Susan ^a   Mazumdar, Madhu ^a   Sadan, Sara ^a   Heineman, Michael ^a   Hirsch, Joy ^a   Kelly, W Kevin ^a   Scher, Howard I ^a   Bajorin, Dean F ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOXORUBICIN; FLUOROURACIL; GALLIUM NITRATE; METHOTREXATE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; VINBLASTINE;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; METASTASIS; MUCOSA INFLAMMATION; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTOPENIA; TRANSITIONAL CELL CARCINOMA; TREATMENT OUTCOME; UROGENITAL TRACT CANCER; WEIGHT REDUCTION;

EID: 0031004485     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1997.15.6.2449     Document Type: Article

References (38)

1. Sternberg CN, Scher HI: Current status of chemotherapy of urothelial tract. Oncology 5:41-49, 1987
2. Sternberg CN, Yagoda A, Scher HI, et al: Methotrexate, vinblastine, doxorubicin and cisplatin for advanced transitional cell carcinoma of the urothelium. Cancer 64:2448-2485, 1989
3. Harker WG, Meyers FJ, Freiha FS, et al: Cisplatin, methotrexate and vinblastine (CMV): An effective chemotherapy regimen for metastatic transitional cell carcinoma of the urothelial tract: A Northern California Oncology Group study. J Clin Oncol 3:1463-1470, 1985
4. Loehrer PJ, Einhorn LH, Elson PJ, et al: A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine and doxorubicin in patients with metastatic urothelial carcinoma: A Cooperative Group study. J Clin Oncol 10:1066-1073, 1992
5. Logothetis CJ, Dexeus FH, Finn L, et al: A prospective randomized trial comparing M-VAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J Clin Oncol 8:1050-1055, 1990
6. Saxman SB, Loehrer PJ, Propery K, et al: Long-term follow-up of phase II intergroup study of M-VAC vs cisplatin in metastatic urothelial carcinoma. Proc Am Soc Clin Oncol 15:631, 1996 (abstr)
7. Geller NL, Sternberg CN, Penenberg D, et al: Prognostic factors for survival of patients with advanced urothelial tumors treated with methotrexate, vinblastine, doxorubicin and cisplatin chemotherapy. Cancer 67:1525-1531, 1991
8. Logothetis CJ, Dexeus F, Sella A, et al: Escalated therapy for refractory urothelial tumors: Methotrexate, vinblastine, doxorubicin and cisplastin plus unglycosylated recombinant human granulocyte-macrophage colony-stimulating factor. J Natl Cancer Inst 82:667-672, 1990
9. Seidman AD, Scher HI, Gabrilove JL, et al: Dose-intensification of methotrexate, vinblastine, doxorubicin, and cisplatin with recombinant granulocyte-colony stimulating factor as initial therapy in advanced urothelial cancer. J Clin Oncol 10:414-420, 1992
10. Gabrilove JL, Jakubowski A, Scher HI, et al: Effect of granulocyte colony-stimulating factor in neutropenia and associated morbidity due to chemotherapy for transitional cell carcinoma of the urothelium. N Engl J Med 318:1414-1422, 1988
11. Moore MJ, Tannock IF, Iscoe N, et al: A phase II study of methotrexate, vinblastine, doxorubicin and cisplatin (MVAC) + GM-CSF in patients with advanced transitional cell carcinoma. Proc Am Soc Clin Oncol 11:199, 1992 (abstr)
12. Loehrer PJ, Nichols CR, Elson P. et al: Escalated dosages of methotrexate, vinblastine, doxorubicin and cisplatin plus rh-G-CSF in advanced urothelial carcinoma: An ECOG trial. J Clin Oncol 12:483-488, 1994
13. Sternberg C, de Mulder P, van Oosterom AT, et al: Intensified M-VAC chemotherapy and recombinant human granulocyte-macrophage colony stimulating factor (GM-CSF) in patients with advanced urothelial tract tumors. Proc Am Soc Clin Oncol 11:210, 1992 (abstr)
14. Logothetis CJ, Sella A, Amato R, et al: Escalated M-VAC +/- rh-GM-CSF in patients with advanced transitional cell carcinoma of the bladder. Proc Am Soc Clin Oncol 10:422, 1991 (abstr)
15. Foster BJ, Claggett-Carr K, Hoth D, et al: Gallium nitrate: The second metal with clinical activity. Cancer Treat Rep 70:1311-1319, 1986
16. Hart MM, Smith CF, Yancey ST, et al: Toxicity and antitumor activity of gallium nitrate and periodically related metal salts. J Nat Cancer Inst 7:1121-1127, 1971
17. Adamson RH, Cannellos GP, Sieber SM: Studies on the antitumor activity of gallium nitrate and other group IIIA metal salts. Cancer Chemother Rep 59:599-610, 1975
18. Warrell RP, Coonley CJ, Straus DJ, et al: Treatment of patients with advanced malignant lymphoma using gallium nitrate as a 7 day continuous infusion. Cancer 51:1982-1987, 1983
19. Samson MK, Fraile RJ, Baker LH, et al: Phase I-II clinical trial of gallium nitrate. Cancer Clin Trials 3:131-136, 1980
20. Saiers JH, Baker LH, Costanzi JH, et al: Treatment of metastatic bladder cancer with gallium nitrate. 13th International Congress of Chemotherapy, Vienna, Austria, 1983, pp 240-284
21. Seidman AD, Scher HI, Heinemann MH, et al: Continuous infusion gallium nitrate for patients with advanced refractory urothelial tract tumors. Cancer 68:1561-1565, 1991
22. Seligman PA, Crawford ED: Treatment of advanced transitional cell carcinoma of the bladder with constant infusion gallium nitrate. J Natl Cancer Inst 83:1582-1584, 1991
23. Yagoda A: Chemotherapy of metastatic bladder cancer. Cancer 45:1879-1888, 1980
24. Carter SK, Wasserman TH: The chemotherapy of urologic cancer. Cancer 36:729-747, 1975
25. Kish JA, Ensley JF, Jacobs J, et al: A randomized trial of cisplatin (CACP) + 5-fluorouracil (5-FU) infusion and CACP + 5-FU bolus for recurrent and advanced squamous cell carcinoma of the head and neck. Cancer 56:2740-2744, 1985
26. Kish JA, Weaver A, Jacobs J, et al: Cisplatin and 5-fluorouracil infusion in patients with recurrent and disseminated epidermoid cancer of the head and neck. Cancer 53:1819-1824, 1984
27. Dy C, Gil A, Algarra SM, et al: Combination chemotherapy of cisplatinum and 5-FU in advanced colorectal carcinoma. Cancer Treat Rep 70:465-468, 1986
28. Amoroso D, Pronzato P, Bertelli G. et al: Cisplatin and 5-fluorouracil in refractory breast cancer patients: A phase II study. Breast Cancer Res Treat 11:269-271, 1988
29. Shultz P, Bajorin D, Kelly WK, et al: Combination gallium nitrate and 5-fluorouracil for platinum-resistant metastatic transitional cell carcinoma of the bladder. Proc Am Assoc Cancer Res 34:203, 1993 (abstr)
30. Amiel J, Quintensh D, Thyss A, et al: Transurethral resection (TUR) and chemotherapy as primary treatment of pTs, pT3, and pT4 bladder cancer. Second International Congress on Chemotherapy 21:177, 1988 (abstr)
31. StatExact User Manuel, Version 2. Cambridge, MA, CYTEL Software Corporation, 1991
32. SAS/STAT User's Guide, vol 2, Version 6, (ed 4). Cary, NC, SAS Institute Inc, 1992
33. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
34. Einhorn LH, Roth BS, Ansari R, et al: Phase II trial of vinblastine, ifosfamide and gallium combination chemotherapy in metastatic urothelial cancer. J Clin Oncol 12:2271-2276, 1994
35. Dreicer R, Roth B, Propert K, et al: Vinblastine, ifosfamide and gallium nitrate (VIG) in advanced carcinoma of the urothelium: A phase II trial of the Eastern Cooperative Oncology Group (ECOG). Proc Am Soc Clin Oncol 14:659, 1995 (abstr)
36. Choi SC, Smith PJ, Becker DP: Early decision in clinical trials when the treatment differences are small. Control Clin Trials 6:280-288, 1985
37. Evans WK, Eisenhauer EA, Cormier Y, et al: Phase II study of amonafide: Results of treatment and lessons learned from the study of an investigational agent in previously untreated patients with extensive small-cell lung cancer. J Clin Oncol 8:390-395, 1990
38. Blackstein M, Eisenhauer EA, Weirzbicki R, et al: Epirubicin in extensive small-cell lung cancer - A phase II study in previously untreated patients: A National Cancer Institute of Canada Clinical Trials Group study. J Clin Oncol 8:385-389, 1990